- Home
- INCY vs FWONA Comparison
INCY vs FWONA Comparison
Compare INCY & FWONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | FWONA |
|---|---|---|
| Founded | 1991 | 1950 |
| Country | United States | United States |
| Employees | N/A | 1674 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 20.0B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | INCY | FWONA |
|---|---|---|
| Price | $117.60 | $93.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $103.52 | $101.75 |
| AVG Volume (30 Days) | ★ 1.7M | 173.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4173.33 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $3,394,635,000.00 | N/A |
| Revenue This Year | $10.44 | $24.56 |
| Revenue Next Year | $10.99 | $5.52 |
| P/E Ratio | ★ $79.38 | $97.75 |
| Revenue Growth | ★ 13.67 | N/A |
| 52 Week Low | $67.17 | $73.70 |
| 52 Week High | $118.97 | $99.49 |
Technical Indicators
Market Signals| Indicator | INCY | FWONA |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 69.01 |
| Support Level | $98.50 | $85.14 |
| Resistance Level | $118.97 | $95.87 |
| Average True Range (ATR) | 3.02 | 2.47 |
| MACD | -0.25 | 0.32 |
| Stochastic Oscillator | 78.21 | 90.02 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. It operates in two reportable segment Formula 1 and MotoGP. It generates majority of its revenue from the Formula 1 segment. The company derives its maximum revenue from United Kingdom.